Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 5, 2012, Pages 454-461

  Nagasawa, Tasuku ^a   Hye Khan, Md Abdul ^a   Imig, John D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Afferent arterioles; Albuminuria; Glomerular injury; Hypertension; Nephrinuria; Vascular endothelial growth factor inhibitors

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALBUMIN; CAPTOPRIL; NEPHRIN; SORAFENIB;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOREGULATION; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DRUG MECHANISM; GLOMERULOPATHY; HYPERTENSION; KIDNEY INJURY; MALE; NEPHRINURIA; NONHUMAN; PROTEINURIA; RAT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; URINARY CAST; URINARY EXCRETION; VASOCONSTRICTION;

ACUTE KIDNEY INJURY; ANIMALS; BENZENESULFONATES; CAPTOPRIL; GROWTH INHIBITORS; HYPERTENSION; MALE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860226420     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2012.05699.x     Document Type: Article

References (53)

1. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: What are the important clinical markers to target? Oncologist 2010; 15: 130-41.
2. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001; 411: 355-65.
3. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57: 4593-9.
4. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13: 9-22.
5. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann. Oncol. 2008; 19: 927-34.
6. Herbst RS. Toxicities of anti-angiogenic therapy in non-small-cell lung cancer. Clin. Lung Cancer 2006; 8(Suppl.): S23-30.
7. Faivre S, Sablin MP, Dreyer C, Raymond E. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. Endocrinol. Metab. Clin. North Am. 2010; 39: 811-26.
8. Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: Update for the internist. Am. J. Med. 2009; 122: 322-8.
9. Okuno Y, Kume H, Hosoda C, Homma Y. Development of nephrotic syndrome after administration of sorafenib in a case of metastatic renal cell carcinoma. Case Rep. Med. 2011; 2011: 710216. Epub 5 October 2011. doi: 10.1155/2011/710216.
10. Van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: Clinical toxicity, therapeutic target, or novel biomarker? J. Clin. Oncol. 2007; 25: 2993-5.
11. Wilhelm S, Chien DS. BAY 43-9006: Preclinical data. Curr. Pharm. Des. 2002; 8: 2255-7.
12. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol. 2008; 47: 176-86.
13. Gupta R, Maitland ML. Sunitinib, hypertension, and heart failure: A model for kinase inhibitor-mediated cardiotoxicity. Curr. Hypertens. Rep. 2011; 13: 430-5.
14. Escalante CP, Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: Basics for primary care providers. Cardiol. Res. Pract. 2011; 2011: 816897. Epub 10 May 2011; doi:10.4061/2011/816897.
15. Langenberg MH, Van Herpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy. Results from a Phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J. Clin. Oncol. 2009; 27: 6152-9.
16. Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to anti-angiogenic therapy: Experience with bevacizumab. Anticancer Res. 2007; 27: 3465-70.
17. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann. Oncol. 2009; 20: 807-15.
18. Park YH, Roh SY, Lee YC. Effect of sorafenib on experimental choroidal neovascularization in the rat. Clin. Exp. Ophthalmol. 2010; 38: 718-26.
19. Ernsberger P, Johnson JL, Rosenthal T, Mirelman D, Koletsky RJ. Therapeutic actions of allylmercaptocaptopril and captopril in a rat model of metabolic syndrome. Am. J. Hypertens. 2007; 20: 866-74.
20. Swislocki AL, LaPier TL, Khuu DT, Fann KY, Tait M, Rodnick KJ. Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats. Am. J. Hypertens. 1999; 12: 581-9.
21. Gu FM, Li QL, Gao Q, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J. Gastroenterol. 2011; 17: 3922-32.
22. Pèrez De Lema G, De Wit C, Cohen CD, et al. Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice. J. Pharmacol. Exp. Ther. 2003; 307: 275-81.
23. Turoni CM, Reynoso HA, Maraòûn RO, Coviello A, Peral de Bruno M. Structural changes in the renal vasculature in streptozotocin-induced diabetic rats without hypertension. Nephron Physiol. 2005; 99: 50-7.
24. Bowers MC, Katki KA, Rao A, et al. Role of calcitonin gene-related peptide in hypertension-induced renal damage. Hypertension 2005; 46: 51-7.
25. + channels. Microcirculation 2008; 15: 137-50.
26. Imig JD, Pham BT, LeBlanc EA, Reddy KM, Falck JR, Inscho EW. Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. Hypertension 2000; 35: 307-12.
27. Guan Z, Inscho EW. Role of adenosine 5′-triphosphate in regulating renal microvascular function and in hypertension. Hypertension 2011; 58: 333-40.
28. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol. 2006; 24: 1363-9.
29. Kappers MH, Smedts FM, Horn T, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 2011; 58: 295-302.
30. Kappers MH, de Beer VJ, Zhou Z, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012; 59: 151-7.
31. Chen SX, Song T, Zhou SH, Liu YH, Wu SJ, Liu LY. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats. Eur. J. Pharmacol. 2008; 584: 368-75.
32. Liu XP, Pang YJ, Zhu WW, et al. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Clin. Exp. Pharmacol. Physiol. 2009; 36: 287-96.
33. Brower GL, Levick SP, Janicki JS. Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am. J. Physiol. Heart Circ. Physiol. 2007; 292: H3057-64.
34. Yamamoto D, Takai S, Jin D, Inagaki S, Tanaka K, Miyazaki M. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J. Mol. Cell. Cardiol. 2007; 43: 670-6.
35. Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ, Wedge SR. Inhibition of vascular endothelial growth factor-A signaling induces hypertension: Examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant anti-hypertensive therapy. Clin. Cancer Res. 2008; 14: 3124-31.
36. Gu JW, Manning RD Jr, Young E, Shparago M, Sartin B, Bailey AP. Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009; 297: R142-8.
37. Mori T, Cowley AW Jr. Role of pressure in angiotensin II-induced renal injury: Chronic servo-control of renal perfusion pressure in rats. Hypertension 2004; 43: 752-9.
38. Ihara G, Kiyomoto H, Kobori H, et al. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: Effect of angiotensin II blockade. J. Hypertens. 2010; 28: 2289-98.
39. Mori T, Cowley AW Jr, Ito S. Molecular mechanisms and therapeutic strategies of chronic renal injury. Physiological role of angiotensin II-induced oxidative stress in renal medulla. J. Pharmacol. Sci. 2006; 100: 2-8.
40. Honkanen EO, Teppo AM, Gronhagen-Riska C. Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulo-nephritis. Kidney Int. 2000; 57: 2343-9.
41. Wolf G, Chen S, Ziyadeh F. From the periphery of the glomerular capillary wall toward the center of disease. Podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-34.
42. Yuan HT, Li XZ, Pitera JE, Long DA, Woolf AS. Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxia inducible factor-1. Am. J. Pathol. 2003; 163: 2289-301.
43. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal disease. J. Clin. Invest. 2003; 111: 707-16.
44. Hauser PV, Collino F, Bussolati B, Camussi G. Nephrin and endothelial injury. Curr. Opin. Nephrol. Hypertens. 2009; 18: 3-8.
45. Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD. Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension 2008; 51: 352-9.
46. Dai HY, Zheng M, Tang RN, et al. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy. Am. J. Med. Sci. 2011; 341: 207-14.
47. Agabiti-Rosei E. Structural and functional changes of the microcirculation in hypertension: Influence of pharmacological therapy. Drugs 2003; 63: 19-29.
48. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 2003; 278: 12605-8.
49. Kitakaze M, Node K, Minamino T, et al. Inhibition of angiotensin-converting enzyme increases the nitric oxide levels in canine ischemic myocardium. J. Mol. Cell. Cardiol. 1998; 30: 2461-6.
50. Persson PB. Renal blood flow auto-regulation in blood pressure control. Curr. Opin. Nephrol. Hypertens. 2002; 11: 67-72.
51. Inscho EW, Carmines PK, Cook AK, Navar LG. Afferent arteriolar responsiveness to altered perfusion pressure in renal hypertension. Hypertension 1990; 15: 748-52.
52. Inscho EW, Cook AK, Murzynowski JB, Imig JD. Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation. J. Hypertens. 2004; 22: 811-8.
53. Inscho EW, Imig JD, Deichmann PC, Cook AK. Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats. J. Am. Soc. Nephrol. 1999; 10 (Suppl.): S178-83.